Design of a “Microbicide” for Prevention of Sexually Transmitted Diseases Using “Inactive” Pharmaceutical Excipients
- 31 March 1999
- journal article
- Published by Elsevier BV in Biologicals
- Vol. 27 (1), 11-21
- https://doi.org/10.1006/biol.1998.0169
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Mucosal disruption due to use of a widely-distributed commercial vaginal productAIDS, 1998
- Summary of the international consensus symposium on advances in the diagnosis, treatment and prophylaxis of cytomegalovirus infectionAntiviral Research, 1996
- Human Immunodeficiency Virus Infection And Other Sexually Transmitted Diseases In Developing Countries: Public Health Importance And Priorities For Resource AllocationThe Journal of Infectious Diseases, 1996
- Seminal Shedding of Human Immunodeficiency Virus Type 1 and Human Cytomegalovirus: Evidence for Different Immunologic ControlsThe Journal of Infectious Diseases, 1995
- Synthesis of Protegrin-Related Peptides and Their Antibacterial and Anti-human Immunodeficiency Virus Activity.CHEMICAL & PHARMACEUTICAL BULLETIN, 1995
- The Incidence of Trichomonas vaginalis in Chronic Prostatitis Patients Determined by Culture Using a Newly Modified Liquid MediumThe Journal of Infectious Diseases, 1992
- Investigations into the Mechanism by Which Sulfated Polysaccharides Inhibit HIV Infection In VitroAIDS Research and Human Retroviruses, 1992
- An insertion vector for the analysis of gene expression during herpes simplex virus infectionGene, 1990
- New Soluble-Formazan Assay for HIV-1 Cytopathic Effects: Application to High-Flux Screening of Synthetic and Natural Products for AIDS-Antiviral ActivityJNCI Journal of the National Cancer Institute, 1989
- INACTIVATION OF HTLV-III/LAV-INFECTED CULTURES OF NORMAL HUMAN LYMPHOCYTES BY NONOXYNOL-9 IN VITROThe Lancet, 1985